Compare Vitrolife AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 14,723 Million (Small Cap)
32.00
NA
1.01%
0.08
4.97%
1.82
Revenue and Profits:
Net Sales:
807 Million
(Quarterly Results - Mar 2026)
Net Profit:
101 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.83%
0%
18.83%
6 Months
-22.26%
0%
-22.26%
1 Year
-30.97%
0%
-30.97%
2 Years
-39.45%
0%
-39.45%
3 Years
-53.29%
0%
-53.29%
4 Years
-50.09%
0%
-50.09%
5 Years
-65.75%
0%
-65.75%
Vitrolife AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.52%
EBIT Growth (5y)
10.99%
EBIT to Interest (avg)
14.33
Debt to EBITDA (avg)
1.08
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.26
Tax Ratio
25.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
11.37%
ROE (avg)
5.51%
Valuation key factors
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
1.60
EV to EBIT
21.71
EV to EBITDA
12.78
EV to Capital Employed
1.55
EV to Sales
3.88
PEG Ratio
NA
Dividend Yield
1.18%
ROCE (Latest)
7.12%
ROE (Latest)
5.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
807.00
891.00
-9.43%
Operating Profit (PBDIT) excl Other Income
242.00
266.00
-9.02%
Interest
20.00
23.00
-13.04%
Exceptional Items
0.00
-5,412.00
100.00%
Consolidate Net Profit
101.00
-5,314.00
101.90%
Operating Profit Margin (Excl OI)
173.50%
179.60%
-0.61%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -9.43% vs 6.71% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 101.90% vs -5,309.80% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,440.00
3,609.00
-4.68%
Operating Profit (PBDIT) excl Other Income
1,043.00
1,238.00
-15.75%
Interest
87.00
109.00
-20.18%
Exceptional Items
-5,427.00
-5.00
-1,08,440.00%
Consolidate Net Profit
-5,012.00
514.00
-1,075.10%
Operating Profit Margin (Excl OI)
179.10%
220.60%
-4.15%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -4.68% vs 2.76% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -1,075.10% vs 113.35% in Dec 2024
About Vitrolife AB 
Vitrolife AB
Pharmaceuticals & Biotechnology
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Company Coordinates 
Company Details
Gustaf Werners gata 2 , GOETEBORG None : 421 32
Registrar Details






